EFFICACY OF VAMANA KARMA (EMESIS THERAPY) IN PRE-DIABETES AND TYPE-II DIABETES MELLITUS: A PILOT STUDY
DOI:
https://doi.org/10.70066/jahm.v1i4.108Keywords:
Vamana Karma, Emesis, Madhumeha, NIDDM, Pre-diabetesAbstract
Background: Diabetes and its complications pose a major threat to future public health resources throughout the world. Based on a compilation of studies from different parts of the world, the World Health Organization (W.H.O.) has projected that the maximum increase in diabetes would occur in India. Though, the discovery of Insulin and other hypoglycemic drugs has a great achievement of modern medical science, but the hazardous side effects of hypoglycemic after long term used are incurable and hence an ideal therapy is still obscure. The Ayurvedic management of Diabetes aims not only to achieve a strict glycemic control but also to treat the root cause of the disease. According to Charak, Sthula Madhumehi (i.e.Type II D.M.) should be managed by Sanshodhana karma (Panchakarma Therapy).
Aims & objectives: To study the efficacy of Vamana (Emesis) in various clinical conditions of Diabetes Mellitus and Obesity.
Material and Methods: The pilot study was conducted in 22 Obese individuals (Both patients and volunteers) where they were performed Vamana with classical methods.
Results: Significant decrease in the levels of S. Triglyceride and insignificant decrease in Fasting Blood Sugar, Serum Cholesterol was observed by Vamana Karma by Classical methods.
Conclusion: Emesis therapy has a better role in the prevention of NIDDM in pre-diabetic subjects and also capable of maintaining the long lasting glycemic control in NIDDM subjects.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ranjip Kumar Dass
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain the copyright of their work and grant the Journal of Ayurveda and Holistic Medicine (JAHM) the right of first publication. All published articles are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) license, which permits non-commercial sharing, use, distribution, and adaptation with proper attribution and the same license terms.
JAHM ensures free, irrevocable, worldwide access to its content. Users may copy, distribute, display, and share published works for non-commercial purposes with appropriate credit to the author(s) and the journal. Limited printed copies for personal, non-commercial use are allowed under the same license.
If a submission is not accepted for publication, the author(s) will be notified.
By submitting, authors confirm that the work is original, that all listed authors have contributed and approved it, and that it does not infringe any third-party rights or duplicate work submitted elsewhere.
